New treatment for all stages of prostate cancer
Official title: Development of VNPP433-3Beta as Novel Therapeutic for All Stages of Prostrate Cancer
Funded at Isoprene Pharmaceuticals, INC. · NIH-11062929 · Data updated 2026-11-12
This study is testing a new oral medication called VNPP433-3β that aims to help people with prostate cancer by targeting the ways the cancer grows and spreads, with the hope of making treatment more effective for patients, even those with advanced stages of the disease.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Isoprene Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | June 4, 2025 |
| Project end | May 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $1,022,522 |
| NIH project number | 1R44CA291285-01A1 |
| Project ID | NIH-11062929 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with prostate cancer at any stage, particularly those who have not responded well to existing treatments.
✕Less likely to help
Patients with non-cancerous conditions or those who have already exhausted all treatment options without any remaining therapeutic avenues may not benefit from this research.
What this research studies
This research focuses on developing VNPP433-3β, a novel therapeutic agent designed to target multiple pathways involved in prostate cancer growth and metastasis. The approach utilizes a unique mechanism that promotes the degradation of specific proteins associated with cancer progression, potentially leading to more effective treatment outcomes. By enhancing the solubility and potency of this compound, the research aims to provide a more effective oral medication for patients with prostate cancer, including those with advanced stages. The study will involve both laboratory and animal testing to evaluate the efficacy and safety of this new treatment.
Why it matters
Potential benefit: If successful, this research could lead to a new, more effective treatment option for patients with prostate cancer, potentially improving survival rates and quality of life.
How similar studies have gone: Previous research has shown promising results with similar multi-targeted approaches in cancer treatment, indicating potential for success with this novel therapeutic.
Where this research is happening
-
Isoprene Pharmaceuticals, INC.
Baltimore, United States Active
Researchers
- Principal investigator: Ramamurthy, Vidya P — Isoprene Pharmaceuticals, INC.
- Study coordinator: Ramamurthy, Vidya P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.